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Abstract The anti-convulsant drug valproate causes hepatic 
failure in a small percentage of patients. We now report that the 
valproate metabolite 2,4-dien-valproate binds (ICs0 = 42 IxM) to 
the cx-subunit of the trifunctional protein responsible for the 
second and third steps in the mitochondrial ]]-oxidation of fatty 
acids. Binding of valproate itself, or of the metabolites 2-en- 
valproate, 4-en-valproate or 3-hydroxy-4-en-valproate, is con- 
siderably weaker. We conclude that valproate-induced hepato- 
toxicity may be due in part to the reversible binding of the 
va|proate metabolite 2,4-dien-valproate or its CoA ester to the cx- 
subunit of the trifunctional protein with consequent inhibition of 
fatty acid oxidation. 
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1. Introduction 
Valproate (2-n-propylpentanoate; Fig. 1) has been used for 
30 years for the treatment of epilepsy. Hepatotoxicity, with 
initial clinical symptoms of nausea, vomiting and lethargy [1], 
is a rare side effect, and animal studies have implicated 4-en- 
valproate (2-n-propyl-4-pentenoate) or a derivative as the 
toxic metabolite [2]. The incidence of hepatotoxicity is higher 
in young children undergoing polytherapy [3], presumably be- 
cause the second anti-convulsant (frequently phenytoin or 
phenobarbital) induces cytochrome P450 which in turn cata- 
lyses the formation of 4-en-valproate [4]. Toxic derivatives of 
4-en-valproyl-CoA may then be generated by formation of the 
CoA derivative and subsequent I]-oxidation within mitochon- 
dria [5]. 
The mitochondrial trifunctional protein (TP) catalyzes three 
consecutive reactions in the oxidation of long chain fatty 
acids. The 78 kDa ~-subunit catalyses the hydration of en- 
oyl-CoA and the dehydrogenation f 3-hydroxyacyl-CoA, and 
the 48-51 kDa 13-subunit catalyses the cleavage of acetyl-CoA 
from the resultant 3-ketoacyl-CoA [6]. Binding of the peptide 
hormone gastrin to the a-subunit of the TP, with an IC50 
value of 200 nM, has been demonstrated by covalent cross- 
linking [7,8]. Gastrin occupies both the hydratase and dehy- 
drogenase active sites of TPct, since substrates of the enoyl- 
CoA hydratase activity, and products of the 3-hydroxyacyl- 
CoA dehydrogenase activity, both compete for gastrin bind- 
ing [8]. Hence the gastrin cross-linking assay provides a con- 
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venient and sensitive assay for active site-directed inhibitors of 
TPa [7,8]. 
TP(x may be the target for the anti-proliferative effects of 
gastrin/cholecystokinin (CCK) receptor antagonists on colon 
cancer cells [8]. Thus, proglumide and benzotript inhibited 
covalent cross-linking of iodinated gastrin to TPa, and the 
observed IC50 values correlated well with the IC50 values for 
inhibition of proliferation of several human colon carcinoma 
cell lines [8]. Presumably inhibition of one or both enzyme 
activities intrinsic to TPc~ by the gastrin/CCK receptor an- 
tagonists proglumide or benzotript leads to a blockade of 
fatty acid oxidation. The resultant reduction in energy supply 
might then inhibit cell proliferation. 
Hereditary defects in the TP can cause death in early child- 
hood [9-11]. A wide range of diagnostic symptoms have been 
reported, including vomiting, hypoketotic hypoglycemic 
coma, myopathy and cardiomyopathy. Pathological examina- 
tion reveals widespread fat deposition in the liver, heart and 
kidneys. Hypothetically, blockade of fatty acid oxidation by 
the TP would reduce the mitochondrial output of acetyl-CoA, 
and hence result in hypoketotic hypoglycemia. The similarity 
in symptoms between patients with valproate-induced hepato- 
toxicity and with mutations in the gene encoding TP~x sug- 
gested the hypothesis that valproate derivatives might also 
target TP~. We have tested the hypothesis by measuring the 
effect of valproate, and the valproate derivatives, 2-en-valpro- 
ate, 4-en-valproate, 2 4-dien-valproate, and 3-hydroxy-4-en- 
valproate (Fig. 1), on the binding of gastrin to TPa. We re- 
port here that 2,4-dien-valproate binds to TP~x with an affinity 
50-fold greater than any other valproate derivative. 
2. Materials and methods 
2.1. Synthesis of valproate derivatives 
Valproic acid was obtained from Sigma (St. Louis, MO). 2-en-val- 
proic acid was obtained from Desitin (Hamburg, Germany). 4-en- 
valproate, 2,4-dien-valproate, and 3-hydroxy-4-en-valproate were 
synthesized asdescribed previously [12]. 
2.2. Gastrin cross-linking assay 
The TP was partially purified from detergent extracts of porcine 
gastric mucosal membranes by lectin and ion-exchange chromatogra- 
phy [7,13]. The following additional protease inhibitors were included 
in all buffers to prevent proteolysis: pepstatin, 1 /.tM; benzamidine, 
1 mM; hexamethylphosphoramide, 0.1%(w/v); aprotinin, 500 U/ml. 
Crosslinking of 125I-NlelS-gastrin2_17 to TPa with disuccinimidylsube- 
rate was measured as described previously [7,8] in the presence of 
increasing concentrations of valproate or valproate metabolites. The 
products of the cross-linking reaction were separated by polyacryla- 
mide gel electrophoresis, and radioactivity associated with TPa was 
detected and quantitated with a phosphorimager (Molecular Dy- 
namics, Sunnyvale, CA). Initial estimates of IC50 values, and of the 
levels of 125I-gastrin2_lr bound in the absence of competitor, were 
S0014-5793196l$12.00 © 1996 Federation of European Biochemical Societies. All rights reserved. 
SSDI S00 14-5793(96)00267-0 
G.S. Baldwin et aLIFEBS Letters 384 (1996) 58~0 59 
valproate 
cytochrorne P450, 
~, esterification 
4-en- 
valproyI-CoA 
CO.SCoA 
l long chain fatty acyI-CoA 
dehydrogenase 
2,4-dien- 
valproyI-CoA 
l long chain enoyI-CoA 
hydratase 
3-hydroxy-4-en- 
valproyI-CoA 
CO.SCoA 
I 
OH 
long chain 3-hydroxy-acyl- 
CoA dehydrogenase 
3-keto-4-en- 
valproyI-CoA 
O 
Fig. 1. Structures of valproate metabolites. Enzymes likely to be in- 
volved in the formation and further metabolism of the inhibitory 
valproate derivative 2,4-dien-valproyl CoA are shown. 3-Keto-4-en- 
valproyl-CoA is probably unstable. 
obtained by fitting the data with the program EBDA, and were re- 
fined with the program LIGAND as described previously [14]. 
3. Results and discussion 
The valproate derivative 2,4-dien-valproate inhibits the 
binding of iodinated gastrin to TPct (Fig. 2). The IC~0 of 
42 + 3 ~tM compares favourably with the value observed for 
the gastrin/CCK receptor antagonist benzotript (200 ~tM [7]). 
Inhibition by valproate and other valproate derivatives was 
considerably weaker (Table 1). The IC50 values measured for 
Table 1 
Binding of valproate metabolites to the trifunctional protein a-sub- 
unit 
Compound IC50 (~tM) 
Valproate 16 000 + 11 000 
2-en-valproate 21 000 + 11 000 
4-en-valproate 28 000 + 9 000 
2,4-dien-valproate 42 _+ 3 
3-Hydroxy-4-en-valproate 2 300 + 1 800 
Binding of valproate metabolites to the t~-subunit of the trifunc- 
tional protein was measured by competition for binding of 1251- 
[NlelS]-gastrin2_17 as described in the legend to Fig. 2. IC~0 values 
(mean + S.D. of at least two experiments) were obtained by compu- 
ter fitting as described previously [14]. 
3-hydroxy-4-en-valproate andvalproate itself were 2.3 and 16 
mM, respectively. Although IC~0 values could not be meas- 
ured accurately for the valproate derivatives 2-en-valproate 
and 4-en-valproate because inhibition did not reach 50% at 
a concentration of 10 mM, estimates of 21 and 28 mM, re- 
spectively, were obtained. Since the natural substrates of TPa 
are CoA esters of long chain fatty acid derivatives, the CoA 
esters of all of the above compounds would presumably bind 
more tightly than the carboxylates. 
There is no evidence at present hat valproate or its metab- 
olites bind covalently to TPct. For example, preincubation of
TPct with valproate metabolites for 2 h at either 4 or 25°C 
does not result in a major reduction in levels of subsequent 
labelling with iodinated gastrin (Fig. 3). The absence of label- 
ling is not surprising when it is considered that reaction be- 
tween 2,4-dien-valproate and glutathione is slow, but that 
reaction between the methyl ester of 2,4-dien-valproate and 
glutathione is fast [12]. By analogy activation of 2,4-dien- 
valproate by formation of its CoA ester may be necessary 
for covalent labelling of TPa  to occur. 
The possibility was also considered that 3-hydroxy-4-en- 
valproate might act as a suicide substrate for TPtz. An uni- 
dentified membrane-bound mitochondrial dehydrogenase r - 
sembling the TP has been shown to catalyse the NAD+-de o
pendent conversion of 3-hydroxy-valproyl-CoA to 3-keto- 
valproyl-CoA [5]. If the TP was also able to catalyse the 
corresponding reaction for 3-hydroxy-4-en-valproate, then 
the instability of the 3-keto-4-en-valproate formed might re- 
sult in the permanent modification and hence inactivation of 
the enzyme. However addition of NAD + to mixtures of TPa 
and 3-hydroxy-4-en-valproate did not result in any further 
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Fig. 2. Binding of valproate metabolites to the trifunctional protein 
0~-subunit. Cross-linking of 125I-[Nle15]-gastrin2_17 to TPa was mea- 
sured as described in section 2 in the presence of increasing concen- 
trations of valproate metabolites. Duplicate samples were subjected 
to electrophoresis on NaDodSO4-polyacrylamide gelsand the radio- 
activity associated with TPa was quantitated by phosphorimager 
scanning, and expressed as a percentage of the value obtained in 
the absence of competitor. The following values for IC50 and for 
the predicted ordinate intercept were obtained by computer fitting 
as described previously [14], and used to construct he indicated 
lines of best fit: (0)  4-en-valproate (38 mM, 99.0%); (v)  2,4-dien- 
valproate (43.9 I.tM, 88.6%). These values were averaged with the re- 
suits of at least one other similar experiment to obtain the mean 
values presented in the text. 
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Fig. 3. Valproate metabolites do not bind irreversibly to the trifunc- 
tional protein a-subunit. Samples of TPct were preincubated with or 
without valproate metabolites in 50 mM HEPES, 0.1% Triton X- 
100, pH 7.6, for 2 h at 4°C. Cross-linking of 125I-[NlelS]-gastrin2_17 
to TPa was then measured at 4°C as described in section 2, and ex- 
pressed as a percentage of the value obtained in the absence of 
valproate metabolites. The concentrations of valproate (V), 2-en- 
valproate (2-EN-V), 4-en-valproate (4-EN-V), or 3-hydroxy-4-en- 
valproate (3-OH-4-EN-VAL) were 1 mM, and of 2,4-dien-valproate 
(2,4-DIEN-V) 10 ~tM. Similar results were obtained when the prein- 
cubation was at 25°C. 
reduction in levels of subsequent labelling with iodinated gas- 
trin (data not shown). 
Does 2,4-dien-valproate inhibit either the long chain enoyl- 
CoA hydratase or the long chain 3-hydroxyacyl-CoA dehy- 
drogenase activity intrinsic to TPcx? It has generally not been 
possible to compare the IC~0 values for inhibitors of gastrin 
binding to TPa with the IC50 values for the same compounds 
as inhibitors of the enzyme activities of TPc~, since the com- 
pounds often absorb strongly in the wavelength range used 
for the spectrophotometric assays. However, benzotript inhi- 
bits both the enoyl-CoA hydratase and the 3-hydroxyacyl- 
CoA dehydrogenase activities of the TP (Hashimoto and 
Baldwin, unpublished ata). It therefore seems likely that 
the valproate derivative 2,4-dien-valproate will also inhibit 
both hydratase and dehydrogenase activities. 
The following hypothetical mechanism (Fig. 1) is therefore 
proposed for valproate-induced hepatotoxicity. Valproate is 
oxidized to 4-en-valproate by cytochrome P450, the levels of 
which may have been elevated by simultaneous treatment with 
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a second enzyme-inducing anti-convulsant. 4-en-valproate is 
then converted to its CoA derivative, and oxidized to 2,4- 
dien-valproyl-CoA by long chain fatty acyl-CoA dehydrogen- 
ase. 2,4-dien-valproyl-CoA binds reversibly to TPct, and com- 
petitively inhibits one or both of the long chain enoyl-CoA 
hydratase and the long chain 3-hydroxyacyl-CoA dehydrogen- 
ase activity intrinsic to TPct. The possibility that covalent 
labelling of TPct by 2,4-dien-valproyl-CoA might lead to irre- 
versible inactivation of the enzyme remains to be investigated. 
In either case blockade of TPct presumably leads to the in- 
hibition of mitochondrial long chain fatty acid oxidation ob- 
served by Kesterson and coworkers [2], with resultant hypo- 
ketotic hypoglycemia. 
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